Control of postprandial state abnormalities: Meeting the challenge of type 2 diabetes?

European Journal of Clinical Investigation, Supplement

Volumn 30, Issue 2, 2000, Pages 19-24

  Puig Domingo, M ^a  

^a HOSPITAL DE MATARÓ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BIGUANIDE; GLIBENCLAMIDE; GLUCOSE; METFORMIN; MIGLITOL; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; FLATULENCE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

EID: 0033867370     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.30.s2.4.x     Document Type: Conference Paper

References (60)

1. 1 Harris MI. Undiagnosed NIDDM. Clinical and public health issues. Diabetes Care 1993;16:642-52.
2. 2 Edelman SV. Type II Diabetes Mellitus. Advances in Internal Medicine. vol. 43. St Louis, MO: Mosby. 1998.p.449-500.
3. 3 American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 (Suppl. 1):S5-S19.
4. 4 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998;15:539-53.
5. 5 Groeneveld Y, Petri H, Hermans J, et al. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabetic Med 1999;16:2-13.
6. 6 Haffner SM. The importance of hyperglycemia in the non-fasting state to the development of cardiovascular disease. Endocrine Rev 1998;19:583-92.
7. 7 Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
8. 8 Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999;20:789-95.
9. 9 Gall M-A, Rossing P, Skott P, et al. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:655-61.
10. 10 UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991;34:877-90.
11. 11 Turner RC, The UK Prospective Diabetes Study. A review. Diabetes Care 1998;21 (Suppl. 3):C35-C38.
12. 12 Stamler J, Vaccaro O, Neaton JD. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
13. 13 Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
14. 14 Pyorala K. Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary heart events as non-diabetic subjects with prior myocardial infarction. Eur Heart J 1999;20:473-75.
15. 15 Standl E. Cardiovascular risk in type 2 diabetes. Diabetes, Obes Metab 1999;1 (Suppl. 2):S24-S36.
16. 16 Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM Occurs at Least 4-7 Years before Clinical Diagnosis. Diabetes Care 1992;15:815-19.
17. 17 Baron AD. Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Practice 1998;40 (Suppl.): S51-S55 .
18. 18 Luddeke H-J. Postprandial hyperglycaemia - its importance and implications. Inst J Clin Pract Suppl 1999;104:3-7.
19. 19 Lebovitz HE. Postprandial hyperglycaemic state: importance and consequences. Diabetes Res Clin Prac 1998;40 (Suppl.): S27-S28.
20. 20 Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM. The Diabetes Intervention Study, 11-year follow-up. Diabetalogia 1996;39:1577-83.
21. 21 Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-67.
22. 22 Fontbonne AM, Eschwèsge E. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991;14:461-69.
23. 23 IDF Task Force on Diabetes Health Economics. Costing Diabetes. The Case for Prevention. Brussels: International Diabetes Federation; 1997.p.1.
24. 24 Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998;21 (Suppl. 3):C19-C24.
25. 25 Jönsson B. The economic impact of diabetes. Diabetes Care 1998;21 (Suppl. 3):C7-10.
26. 26 Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997;78:544-49.
27. 27 King H, Aubert RE, Herman WH. Global burden of diabetes. 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
28. 28 IDF Task Force on Diabetes Health Economics. Diabetes Health Economics. Facts. Figures and Forecasts. Brussels: International Diabetes Federation; 1999.p.1.
29. 29 American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 1999;22:S20-S23.
30. 30 CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
31. 31 Savage PJ, Narayan KMV. Reducing cardiovascular complications of type 2 diabetes. Diabetes Care 1999;22:1769-70.
32. 32 Barzily JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 1999;354:622-25.
33. 33 Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998;40 (Suppl.):S3-S8.
34. 34 Gerstein HC. Dysglycaemia: a cardiovascular risk factor. Diabetes Res Clin Pract 1998;40 (Suppl.):S9-14.
35. 35 Anonymous. Diabetes care, research in Europe. The Saint Vincent Declaration. Diabet Med 1990;7:360.
36. 36 European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabetic Med 1999;16:716-30.
37. 37 American Diabetes Association. Third-party reimbursement for diabetes care, self-management education and supplies. Diabetes Care 1999;22 (Suppl. 1):S105-S106.
38. 38 World Health Organization. Therapeutic Patient Education. Continuing Education Programmes for Healthcare Providers in the Field of Prevention of Chronic Diseases. Copenhagen: World Health Organization Regional Office for Europe;1998.p.1.
39. 39 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
40. 40 Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280:1490-96.
41. 41 Douglas E, Bennie M, McAnaw J, et al. Pharmaceutical care (4): Diabetes mellitus. Pharmaceut J 1998;261:810-18.
42. 42 American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999;22 (Suppl. 1):S32-S41.
43. 43 Dunning T, Martin M. Health professionals' perceptions of the seriousness of diabetes. Pract Diabetes Int 1999;16:73-77.
44. 44 Berger M, Muhlhauser I. Diabetes care and patient-oriented outcomes. JAMA 1999;281:1676-78.
45. 45 Wolffenbuttel BH, Graal MB. New treatments for patients with type 2 diabetes mellitus. Postgrad Med J 1996;72:657-62.
46. 46 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 1993;329:977-86.
47. 47 Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. [Comment.] Lancet 1998;352:832-33.
48. 48 Kuritzky L, Samraj G, Quillen DM. Improving management of type 2 diabetes mellitus: 1. α-glucosidase inhibitors. Hosp Pract 1999;34:43-46.
49. 49 Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49.
50. 50 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
51. 51 Goede P, Vedel P, Parving H-H, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
52. 52 Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Safety 1995;12:32-45.
53. 53 Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36.
54. 54 Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994;17:20-29.
55. 55 Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997;20:687-91.
56. 56 Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515-22.
57. 57 Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabetes Metab 1995;21:162-67.
58. 58 Monnier L. The role of blood glucose-lowering drugs in the light of the UKPDS. Diabetes, Obes Metab 1999;1 (Suppl. 2): S14-S23.
59. 59 Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-45.
60. 60 Rybka J, Goke B, Sissman J. European comparative study of 2 alpha-glucosidase inhibitors, miglitol and acarbose. [Abstract 0433]. ADA; 1999.